189 related articles for article (PubMed ID: 17674358)
1. Pyrimethamine treatment does not ameliorate lymphoproliferation or autoimmune disease in MRL/lpr-/- mice or in patients with autoimmune lymphoproliferative syndrome.
Rao VK; Dowdell KC; Dale JK; Dugan F; Pesnicak L; Bi LL; Hoffmann V; Penzak S; Avila NA; Fleisher TA; Puck JM; Straus SE
Am J Hematol; 2007 Dec; 82(12):1049-55. PubMed ID: 17674358
[TBL] [Abstract][Full Text] [Related]
2. Expression in transgenic mice of dominant interfering Fas mutations: a model for human autoimmune lymphoproliferative syndrome.
Choi Y; Ramnath VR; Eaton AS; Chen A; Simon-Stoos KL; Kleiner DE; Erikson J; Puck JM
Clin Immunol; 1999 Oct; 93(1):34-45. PubMed ID: 10497009
[TBL] [Abstract][Full Text] [Related]
3. Valproic acid (VPA), a histone deacetylase (HDAC) inhibitor, diminishes lymphoproliferation in the Fas -deficient MRL/lpr(-/-) murine model of autoimmune lymphoproliferative syndrome (ALPS).
Dowdell KC; Pesnicak L; Hoffmann V; Steadman K; Remaley AT; Cohen JI; Straus SE; Rao VK
Exp Hematol; 2009 Apr; 37(4):487-94. PubMed ID: 19217201
[TBL] [Abstract][Full Text] [Related]
4. Rapid regression of lymphadenopathy upon rapamycin treatment in a child with autoimmune lymphoproliferative syndrome.
Janić MD; Brasanac CD; Janković JS; Dokmanović BL; Krstovski RN; Kraguljac Kurtović JN
Pediatr Blood Cancer; 2009 Dec; 53(6):1117-9. PubMed ID: 19588524
[TBL] [Abstract][Full Text] [Related]
5. Reversible monoclonal lymphadenopathy in autoimmune lymphoproliferative syndrome with functional FAS (CD95/APO-1) deficiency.
Ströbel P; Nanan R; Gattenlöhner S; Müller-Deubert S; Müller-Hermelink HK; Kreth HW; Marx A
Am J Surg Pathol; 1999 Jul; 23(7):829-37. PubMed ID: 10403307
[TBL] [Abstract][Full Text] [Related]
6. Acceleration of lpr lymphoproliferative and autoimmune disease by transgenic protein kinase CK2 alpha.
Rifkin IR; Channavajhala PL; Kiefer HL; Carmack AJ; Landesman-Bollag E; Beaudette BC; Jersky B; Salant DJ; Ju ST; Marshak-Rothstein A; Seldin DC
J Immunol; 1998 Nov; 161(10):5164-70. PubMed ID: 9820486
[TBL] [Abstract][Full Text] [Related]
7. The use of the anti-malaria drug Fansidar (pyrimethamine and sulphadoxine) in the treatment of a patient with autoimmune lymphoproliferative syndrome and Fas deficiency.
van der Werff ten Bosch JE; Demanet C; Balduck N; Bakkus MH; De Raeve H; Desprechins B; Otten J; Thielemans K
Br J Haematol; 1998 Jul; 102(2):578-81. PubMed ID: 9695976
[TBL] [Abstract][Full Text] [Related]
8. Deletion of receptor for advanced glycation end products exacerbates lymphoproliferative syndrome and lupus nephritis in B6-MRL Fas lpr/j mice.
Goury A; Meghraoui-Kheddar A; Belmokhtar K; Vuiblet V; Ortillon J; Jaisson S; Devy J; Le Naour R; Tabary T; Cohen JH; Schmidt AM; Rieu P; Touré F
J Immunol; 2015 Apr; 194(8):3612-22. PubMed ID: 25762779
[TBL] [Abstract][Full Text] [Related]
9. Rapamycin improves lymphoproliferative disease in murine autoimmune lymphoproliferative syndrome (ALPS).
Teachey DT; Obzut DA; Axsom K; Choi JK; Goldsmith KC; Hall J; Hulitt J; Manno CS; Maris JM; Rhodin N; Sullivan KE; Brown VI; Grupp SA
Blood; 2006 Sep; 108(6):1965-71. PubMed ID: 16757690
[TBL] [Abstract][Full Text] [Related]
10. Clincal, immunologic, and genetic features of an autoimmune lymphoproliferative syndrome associated with abnormal lymphocyte apoptosis.
Sneller MC; Wang J; Dale JK; Strober W; Middelton LA; Choi Y; Fleisher TA; Lim MS; Jaffe ES; Puck JM; Lenardo MJ; Straus SE
Blood; 1997 Feb; 89(4):1341-8. PubMed ID: 9028957
[TBL] [Abstract][Full Text] [Related]
11. Histologic features of sinus histiocytosis with massive lymphadenopathy in patients with autoimmune lymphoproliferative syndrome.
Maric I; Pittaluga S; Dale JK; Niemela JE; Delsol G; Diment J; Rosai J; Raffeld M; Puck JM; Straus SE; Jaffe ES
Am J Surg Pathol; 2005 Jul; 29(7):903-11. PubMed ID: 15958855
[TBL] [Abstract][Full Text] [Related]
12. Fluorodeoxyglucose positron emission tomography (FDG-PET) for monitoring lymphadenopathy in the autoimmune lymphoproliferative syndrome (ALPS).
Rao VK; Carrasquillo JA; Dale JK; Bacharach SL; Whatley M; Dugan F; Tretler J; Fleisher T; Puck JM; Wilson W; Jaffe ES; Avila N; Chen CC; Straus SE
Am J Hematol; 2006 Feb; 81(2):81-5. PubMed ID: 16432855
[TBL] [Abstract][Full Text] [Related]
13. Autoimmune lymphoproliferative syndrome: report of two cases and review of the literature.
Oren H; Ozkal S; Gülen H; Duman M; Uçar C; Atabay B; Yilmaz S; Kargi A; Irken G
Ann Hematol; 2002 Nov; 81(11):651-3. PubMed ID: 12454704
[TBL] [Abstract][Full Text] [Related]
14. Pathological findings in human autoimmune lymphoproliferative syndrome.
Lim MS; Straus SE; Dale JK; Fleisher TA; Stetler-Stevenson M; Strober W; Sneller MC; Puck JM; Lenardo MJ; Elenitoba-Johnson KS; Lin AY; Raffeld M; Jaffe ES
Am J Pathol; 1998 Nov; 153(5):1541-50. PubMed ID: 9811346
[TBL] [Abstract][Full Text] [Related]
15. IFN-gamma receptor signaling is essential for the initiation, acceleration, and destruction of autoimmune kidney disease in MRL-Fas(lpr) mice.
Schwarting A; Wada T; Kinoshita K; Tesch G; Kelley VR
J Immunol; 1998 Jul; 161(1):494-503. PubMed ID: 9647261
[TBL] [Abstract][Full Text] [Related]
16. Autoreactivity accelerates the development of autoimmunity and lymphoproliferation in MRL/Mp-lpr/lpr mice.
Weston KM; Yeh ET; Sy MS
J Immunol; 1987 Aug; 139(3):734-42. PubMed ID: 3110283
[TBL] [Abstract][Full Text] [Related]
17. Reversion of autoimmune lymphoproliferative syndrome with an antimalarial drug: preliminary results of a clinical cohort study and molecular observations.
van der Werff Ten Bosch J; Schotte P; Ferster A; Azzi N; Boehler T; Laurey G; Arola M; Demanet C; Beyaert R; Thielemans K; Otten J
Br J Haematol; 2002 Apr; 117(1):176-88. PubMed ID: 11918552
[TBL] [Abstract][Full Text] [Related]
18. Arsenic trioxide: A promising novel therapeutic agent for lymphoproliferative and autoimmune syndromes in MRL/lpr mice.
Bobé P; Bonardelle D; Benihoud K; Opolon P; Chelbi-Alix MK
Blood; 2006 Dec; 108(13):3967-75. PubMed ID: 16926289
[TBL] [Abstract][Full Text] [Related]
19. Deficiency of gelatinase B/MMP-9 aggravates lpr-induced lymphoproliferation and lupus-like systemic autoimmune disease.
Cauwe B; Martens E; Sagaert X; Dillen C; Geurts N; Li S; Mertens J; Thijs G; Van den Steen PE; Heremans H; De Vos R; Blockmans D; Arnold B; Opdenakker G
J Autoimmun; 2011 May; 36(3-4):239-52. PubMed ID: 21376533
[TBL] [Abstract][Full Text] [Related]
20. Characteristic T helper 2 T cell cytokine abnormalities in autoimmune lymphoproliferative syndrome, a syndrome marked by defective apoptosis and humoral autoimmunity.
Fuss IJ; Strober W; Dale JK; Fritz S; Pearlstein GR; Puck JM; Lenardo MJ; Straus SE
J Immunol; 1997 Feb; 158(4):1912-8. PubMed ID: 9029133
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
